Financial Services
Live Price
Offline$0.98
+7.99% today
1Y Change
+4.68%
Window
Jun 30, 2025 → Jun 17, 2026
Coverage: 14 bars · Jun 30, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioPharma Credit PLC (BOPCF) is a Financial Services stock with a market cap of $1.06B. The stock last traded around $0.98 and up 4.7% across the available one-year price window (Jun 30, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +12.7%, EPS growth of +10.0%, a dividend yield of 10.5%. What stands out right now is revenue +12.7%, EPS +10.0%, free cash flow -18.6% with operating margin 92.5% and ROIC 11.2%. The dividend matters to the case here, with a current yield around 10.5%. Valuation is more restrained than many high-expectation growth names at P/E 8.2 and price/sales 7.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines BOPCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BOPCF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BOPCF Max Drawdown
-11.03%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BOPCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$126.4M
-40.9% YoY
FY Net Income
$85.0M
-53.4% YoY
Free Cash Flow
$96.4M
-47.7% YoY
Revenue Growth
+12.7%
EPS Growth
+10.0%
Gross Margin
93.5%
Net Margin
92.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 140M | 124M | 160M | 214M | 126M |
| Gross Profit | 115M | 124M | 110M | 184M | 88M |
| Operating Income | 130M | 122M | 108M | 182M | 85M |
| EBITDA | 130M | 122M | 0 | 0 | 0 |
| Net Income | 130M | 122M | 108M | 182M | 85M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13M | 6M | 86M | 121M | 95M |
| Total Assets | 1.2B | 1.2B | 1.4B | 1.4B | 1.4B |
| Total Liabilities | 18M | 18M | 16M | 26M | 7M |
| Shareholder Equity | 1.2B | 1.2B | 1.3B | 1.3B | 1.4B |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -13M | -6M | -86M | -121M | -95M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
96M
-47.7% YoY
Capital Expenditures
0
Free Cash Flow
96M
-47.7% YoY
Key ratios
Gross Margin
93.5%
Operating Margin
92.5%
Net Margin
92.6%
ROE
11.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.